Cargando…

Gut Microbiota: The Missing Link Between Helicobacter pylori Infection and Metabolic Disorders?

Helicobacter pylori (H. pylori) is a gram-negative bacterium that infects approximately 4.4 billion individuals worldwide. Although the majority of infected individuals remain asymptomatic, this bacterium colonizes the gastric mucosa causing the development of various clinical conditions as peptic u...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin-Nuñez, Gracia M., Cornejo-Pareja, Isabel, Clemente-Postigo, Mercedes, Tinahones, Francisco J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247771/
https://www.ncbi.nlm.nih.gov/pubmed/34220702
http://dx.doi.org/10.3389/fendo.2021.639856
_version_ 1783716588484034560
author Martin-Nuñez, Gracia M.
Cornejo-Pareja, Isabel
Clemente-Postigo, Mercedes
Tinahones, Francisco J.
author_facet Martin-Nuñez, Gracia M.
Cornejo-Pareja, Isabel
Clemente-Postigo, Mercedes
Tinahones, Francisco J.
author_sort Martin-Nuñez, Gracia M.
collection PubMed
description Helicobacter pylori (H. pylori) is a gram-negative bacterium that infects approximately 4.4 billion individuals worldwide. Although the majority of infected individuals remain asymptomatic, this bacterium colonizes the gastric mucosa causing the development of various clinical conditions as peptic ulcers, chronic gastritis and gastric adenocarcinomas and mucosa-associated lymphoid tissue lymphomas, but complications are not limited to gastric ones. Extradigestive pathologies, including metabolic disturbances such as diabetes, obesity and nonalcoholic fatty liver disease, have also been associated with H. pylori infection. However, the underlying mechanisms connecting H. pylori with extragastric metabolic diseases needs to be clarified. Notably, the latest studies on the topic have confirmed that H. pylori infection modulates gut microbiota in humans. Damage in the gut bacterial community (dysbiosis) has been widely related to metabolic dysregulation by affecting adiposity, host energy balance, carbohydrate metabolism, and hormonal modulation, among others. Taking into account that Type 2 diabetic patients are more prone to be H. pylori positive, gut microbiota emerges as putative key factor responsible for this interaction. In this regard, the therapy of choice for H. pylori eradication, based on proton pump inhibitor combined with two or more antibiotics, also alters gut microbiota composition, but consequences on metabolic health of the patients has been scarcely explored. Recent studies from our group showed that, despite decreasing gut bacterial diversity, conventional H. pylori eradication therapy is related to positive changes in glucose and lipid profiles. The mechanistic insights explaining these effects should also be addressed in future research. This review will deal with the role of gut microbiota as the linking factor between H. pylori infection and metabolic diseases, and discussed the impact that gut bacterial modulation by H. pylori eradication treatment can also have in host’s metabolism. For this purpose, new evidence from the latest human studies published in more recent years will be analyzed.
format Online
Article
Text
id pubmed-8247771
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82477712021-07-02 Gut Microbiota: The Missing Link Between Helicobacter pylori Infection and Metabolic Disorders? Martin-Nuñez, Gracia M. Cornejo-Pareja, Isabel Clemente-Postigo, Mercedes Tinahones, Francisco J. Front Endocrinol (Lausanne) Endocrinology Helicobacter pylori (H. pylori) is a gram-negative bacterium that infects approximately 4.4 billion individuals worldwide. Although the majority of infected individuals remain asymptomatic, this bacterium colonizes the gastric mucosa causing the development of various clinical conditions as peptic ulcers, chronic gastritis and gastric adenocarcinomas and mucosa-associated lymphoid tissue lymphomas, but complications are not limited to gastric ones. Extradigestive pathologies, including metabolic disturbances such as diabetes, obesity and nonalcoholic fatty liver disease, have also been associated with H. pylori infection. However, the underlying mechanisms connecting H. pylori with extragastric metabolic diseases needs to be clarified. Notably, the latest studies on the topic have confirmed that H. pylori infection modulates gut microbiota in humans. Damage in the gut bacterial community (dysbiosis) has been widely related to metabolic dysregulation by affecting adiposity, host energy balance, carbohydrate metabolism, and hormonal modulation, among others. Taking into account that Type 2 diabetic patients are more prone to be H. pylori positive, gut microbiota emerges as putative key factor responsible for this interaction. In this regard, the therapy of choice for H. pylori eradication, based on proton pump inhibitor combined with two or more antibiotics, also alters gut microbiota composition, but consequences on metabolic health of the patients has been scarcely explored. Recent studies from our group showed that, despite decreasing gut bacterial diversity, conventional H. pylori eradication therapy is related to positive changes in glucose and lipid profiles. The mechanistic insights explaining these effects should also be addressed in future research. This review will deal with the role of gut microbiota as the linking factor between H. pylori infection and metabolic diseases, and discussed the impact that gut bacterial modulation by H. pylori eradication treatment can also have in host’s metabolism. For this purpose, new evidence from the latest human studies published in more recent years will be analyzed. Frontiers Media S.A. 2021-06-17 /pmc/articles/PMC8247771/ /pubmed/34220702 http://dx.doi.org/10.3389/fendo.2021.639856 Text en Copyright © 2021 Martin-Nuñez, Cornejo-Pareja, Clemente-Postigo and Tinahones https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Martin-Nuñez, Gracia M.
Cornejo-Pareja, Isabel
Clemente-Postigo, Mercedes
Tinahones, Francisco J.
Gut Microbiota: The Missing Link Between Helicobacter pylori Infection and Metabolic Disorders?
title Gut Microbiota: The Missing Link Between Helicobacter pylori Infection and Metabolic Disorders?
title_full Gut Microbiota: The Missing Link Between Helicobacter pylori Infection and Metabolic Disorders?
title_fullStr Gut Microbiota: The Missing Link Between Helicobacter pylori Infection and Metabolic Disorders?
title_full_unstemmed Gut Microbiota: The Missing Link Between Helicobacter pylori Infection and Metabolic Disorders?
title_short Gut Microbiota: The Missing Link Between Helicobacter pylori Infection and Metabolic Disorders?
title_sort gut microbiota: the missing link between helicobacter pylori infection and metabolic disorders?
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247771/
https://www.ncbi.nlm.nih.gov/pubmed/34220702
http://dx.doi.org/10.3389/fendo.2021.639856
work_keys_str_mv AT martinnunezgraciam gutmicrobiotathemissinglinkbetweenhelicobacterpyloriinfectionandmetabolicdisorders
AT cornejoparejaisabel gutmicrobiotathemissinglinkbetweenhelicobacterpyloriinfectionandmetabolicdisorders
AT clementepostigomercedes gutmicrobiotathemissinglinkbetweenhelicobacterpyloriinfectionandmetabolicdisorders
AT tinahonesfranciscoj gutmicrobiotathemissinglinkbetweenhelicobacterpyloriinfectionandmetabolicdisorders